封面
市場調查報告書
商品編碼
1304374

品牌非專利市場:醫藥品分類,各製劑,各適應症,各流通管道,各地區- 市場規模,佔有率,展望,機會分析,2023年~2030年

Branded Generics Market, By Drug Class By Formulation, By Indication, Distribution Channel and By Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

出版日期: | 出版商: Coherent Market Insights | 英文 176 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場動態

ANDA批准的增加是支持市場增長的主要因素。根據德里藥物科學研究大學 2023 年 3 月 7 日發表的一篇文章,2022 年期間批准了 742 項 ANDA(簡略新藥申請),同比增長 17%。此外,還有 136 個臨時批准,與最終批准(117 個)一樣,與 2021 年相比仍在增長。今年的批准數量比去年增加了88個,印度企業的貢獻很大。由於品牌仿製藥價格實惠,對仿製藥的需求也激增。

本調查的主要特徵

  • 本報告提供以2021年為基準年的預測期間(2022-2030 年)之全球品牌非專利市場的市場規模和復合年增長率(CAGR %)相關的詳細分析。
  • 並闡明不同部門市場的潛在收入機會,說明該市場具有魅力的投資主張矩陣。
  • 同時並提供市場推動因素和限制、機會、新產品發布或批准、市場趨勢、區域前景和主要參與者採用的競爭戰略等重要考察。
  • 並基於企業亮點,各類型投資組合、主要焦點、財務業績和市場策略等參數,介紹全球品牌非專利市場的主要參與者之企業簡介。
  • 藉由該報告提供的洞察,將能幫助營銷人員和公司高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
  • 全球牛血清市場報告配合該行業的各種利益相關者,包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
  • 利益相關者可以透過全球品牌非專利市場用於分析的各種戰略矩陣來幫助他們更容易做下決策。

目錄

第1章 調查的目的與前提

  • 調查的目的
  • 前提條件
  • 簡稱

第2章 市場展望

  • 報告的說明
    • 市場定義和範圍
  • 摘要整理
  • 連貫·商機·地圖(COM)

第3章 市場動態,法規,趨勢分析

  • 市場動態
  • 促進因素
  • 阻礙因素
  • 市場機會
  • 影響分析
  • 最近的產品銷售
  • 流行病學
  • 合併,收購,及的合作
  • 法規情勢
  • 主要的發展
  • PEST分析

第4章 品牌非專利的全球市場:COVID-19影響分析

  • 經濟影響
  • 新型冠狀病毒感染疾病(COVID-19)的流行病學
  • 需求與供給的影響

第5章 品牌非專利的全球市場:醫藥品分類,2018~2030年

  • 烷化劑
  • 抗代謝物
  • 荷爾蒙
  • 降壓劑
  • 脂質低墮胎藥
  • 抗憂鬱症藥
  • 抗精神病藥
  • 抗癲癇藥
  • 其他

第6章 品牌非專利的全球市場:各製劑,2018~2030年

  • 口服
  • 非口服
  • 討論價值
  • 其他

第7章 品牌非專利的全球市場:各適應症,2018~2030年

  • 腫瘤學
  • 心血管疾病
  • 糖尿病
  • 神經內科
  • 消化器官疾病
  • 皮膚科的病
  • 止痛藥及抗發炎劑
  • 其他

第8章 品牌非專利的全球市場:各流通管道,2018~2030年

  • 醫院藥局
  • 零售藥局
  • 線上藥局
  • 藥妝店

第9章 品牌非專利的全球市場:各地區,2018~2030年

  • 北美
  • 美國
  • 加拿大
  • 南美
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他南美國家
  • 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太地區
  • 中東
  • GCC
  • 以色列
  • 其他中東
  • 非洲
  • 北非
  • 中非
  • 南非

第10章 競爭情形

  • Mylan N.V
    • Novartis AG
  • Teva Pharmaceutical Industries Ltd
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Aspen Pharmacare Holding Ltd.
  • Abbott Laboratories
  • Valeant Pharmaceuticals International, Inc.

第11章 章節

  • 調查手法
  • 關於出版社
簡介目錄
Product Code: CMI3391

Branded generic is a generic drug, which is manufactured by either original manufacturer after patent expiry of the brand, or is manufactured by a generic manufacturer. Branded generic has to go through abbreviated new drug application (ANDA) process before it can be marketed. Branded generic are cheaper than their branded counterparts but can be costlier than generic versions of the drug. Branded generic is defined as a product that is a novel dosage form of a branded off-patent medicine, and is manufactured by a different manufacturer than originator, or a molecule copy of an off-patent product with a trade name. Branded generics can also be different salts of an FDA-approved brand name drug.

It is easy to confuse branded generics with authorized generics, but they are not the same. Branded generics go through the same FDA approval process as other generics after branded drug patents expire. Authorized generics, however, are created by makers of branded drugs, under the same NDA (New Drug Approval) authorization as the original branded drug, and they may be sold before drug patents expire.

Market Dynamics

Rising ANDA approvals is a major factor which is supporting the market growth. According to an article published by Delhi Pharmaceutical Sciences & Research University on March 7 2023, a total of 742 Abbreviated New Drug Application (ANDA) approvals were granted during the calendar year 2022, registering a growth of 17% over last year. Additionally, 136 Tentative Approvals were also granted, again a similar growth over 2021 numbers (117) as seen for final ANDA approvals. Indian players contributed a large proportion of the incremental number of approvals this year with 88 more approvals than last year. Additionally, demand for generic medications is in surge owing to the affordable prices of branded generics.

Key features of the study:

  • This report provides an in-depth analysis of the global branded generics market and provides market size (US$ Million) and compound annual growth rate (CAGR) of 7.30% for the forecast period (2023-2030), considering 2022 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global branded generics market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Mylan N.V, Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Aspen Pharmacare Holding Ltd., Abbott Laboratories, and Valeant Pharmaceuticals International, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • Global branded generics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global branded generics market.

Detailed Segmentation:

  • Global Branded Generics Market, By Drug Class:
    • Alkylating Agents
    • Antimetabolites
    • Hormones
    • Anti-Hypertensive
    • Lipid Lowering Drugs
    • Anti-Depressants
    • Anti-Psychotics
    • Anti-Epileptics
    • Others
  • Global Branded Generics Market, By Formulation:
    • Oral
    • Parenteral
    • Topical
    • Others
  • Global Branded Generics Market, By Indication:
    • Oncology
    • Cardiovascular Diseases
    • Diabetes
    • Neurology
    • Gastrointestinal Diseases
    • Dermatology Diseases
    • Analgesics and Anti-inflammatory
    • Others
  • Global Branded Generics Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Drug Stores Global Branded generics Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country:
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
      • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • Mylan N.V*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Aspen Pharmacare Holding Ltd.
    • Abbott Laboratories
    • Valeant Pharmaceuticals International, Inc

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Class
    • Market Snapshot, By Formulation
    • Market Snapshot, By Indication
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
  • Impact Analysis
  • Recent Product Launches
  • Epidemiology
  • Merger, Acquisition, and Collaborations
  • Regulatory Scenario
  • Key Developments
  • PEST Analysis

4. Global Branded Generics Market- COVID-19 Impact Analysis

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global Branded Generics Market, By Drug Class, 2018 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Alkylating Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Antimetabolites
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Hormones
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Anti-Hypertensive
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Lipid Lowering Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Anti-Depressants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Anti-Psychotics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Anti-Epileptics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

6. Global Branded Generics Market, By Formulation, 2018 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Parenteral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Topical
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

7. Global Branded Generics Market, By Indication, 2018 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Oncology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Cardiovascular Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Diabetes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Neurology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Gastrointestinal Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Dermatology Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Analgesics and Anti-inflammatory
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

8. Global Branded Generics Market, By Distribution Channel, 2018 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Drug Stores
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

9. Global Branded Generics Market, By Region, 2018 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Formulation: , 2018 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Million)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018- 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Formulation: , 2018- 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018- 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Formulation: , 2018- 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Million)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018- 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Formulation: , 2018- 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Million)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018- 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Formulation: , 2018- 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Million)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018- 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Formulation: , 2018- 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

  • Mylan N.V
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
    • Novartis AG
  • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Teva Pharmaceutical Industries Ltd
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sun Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Aspen Pharmacare Holding Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Abbott Laboratories
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Valeant Pharmaceuticals International, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies

11. Section

  • Research Methodology
  • About Us